Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin

被引:75
作者
Robbins, RJ
Tuttle, RM
Sonenberg, M
Shaha, A
Sharaf, R
Robbins, H
Fleisher, M
Larson, SM
机构
[1] Mem Sloan Kettering Canc Ctr, Mem Hosp Canc & Allied Dis, Dept Endocrinol, Serv Endocrinol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Mem Hosp Canc & Allied Dis, Nucl Med Serv, New York, NY 10021 USA
[3] Mem Hosp Canc & Allied Dis, Mem Sloan Kettering Canc Ctr, Head & Neck Surg Serv, New York, NY 10021 USA
[4] Mem Hosp Canc & Allied Dis, Mem Sloan Kettering Canc Ctr, Clin Chem Serv, New York, NY 10021 USA
[5] Mem Hosp Canc & Allied Dis, Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[6] Mem Hosp Canc & Allied Dis, Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA
[7] Mem Hosp Canc & Allied Dis, Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
[8] Mem Hosp Canc & Allied Dis, Mem Sloan Kettering Canc Ctr, Clin Labs, New York, NY 10021 USA
关键词
D O I
10.1089/105072501316973127
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Radioiodine ablation (RA) of normal thyroid remnants after thyroidectomy for differentiated thyroid carcinoma improves the sensitivity of subsequent radioiodine scans and serum thyroglobulin measurements for detection of residual thyroid carcinoma. Local cancer recurrences are also lower after RA. One standard preparation for RA involves rendering the patient hypothyroid in order to stimulate endogenous thyrotropin (TSH) secretion and sodium iodide symporter (NIS) activity. An alternative approach is to prescribe thyroxine after thyroidectomy and to stimulate NIS with exogenous recombinant human thyrotropin (rhTSH). This latter approach was used in 10 patients at our medical center. Complete resolution of all visible I-131 thyroid bed uptake was achieved in all when follow-up scans were performed 5 to 13 months later. This approach has the potential to successfully ablate thyroid remnants without the need to induce hypothyroidism.
引用
收藏
页码:865 / 869
页数:5
相关论文
共 25 条
[1]  
Adler M L, 1998, Endocr Pract, V4, P282
[2]  
Bal C, 1996, CANCER, V77, P2574, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2574::AID-CNCR22>3.3.CO
[3]  
2-S
[4]  
BENUA RS, 1962, AMER J ROENTGENOL RA, V87, P171
[5]   Isolated thyrotropin deficiency secondary to primary empty sella in a patient with differentiated thyroid carcinoma: An indication for recombinant thyrotropin [J].
Colleran, KM ;
Burge, MR .
THYROID, 1999, 9 (12) :1249-1252
[6]   Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy [J].
de Klerk, JMH ;
de Keizer, B ;
Zelissen, PMJ ;
Lips, CMJ ;
Koppeschaar, HPF .
NUCLEAR MEDICINE COMMUNICATIONS, 2000, 21 (06) :529-532
[7]   Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy [J].
Dow, KH ;
Ferrell, BR ;
Anello, C .
THYROID, 1997, 7 (04) :613-619
[8]   Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer [J].
Durski, JM ;
Weigel, RJ ;
McDougall, IR .
NUCLEAR MEDICINE COMMUNICATIONS, 2000, 21 (06) :521-528
[9]  
Furhang EE, 1999, J NUCL MED, V40, P131
[10]   A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer [J].
Haugen, BR ;
Pacini, F ;
Reiners, C ;
Schlumberger, M ;
Ladenson, PW ;
Sherman, SI ;
Cooper, DS ;
Graham, KE ;
Braverman, LE ;
Skarulis, MC ;
Davies, TF ;
DeGroot, LJ ;
Mazzaferri, EL ;
Daniels, GH ;
Ross, DS ;
Luster, M ;
Samuels, MH ;
Becker, DV ;
Maxon, HR ;
Cavalieri, RR ;
Spencer, CA ;
McEllin, K ;
Weintraub, BD ;
Ridgway, EC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (11) :3877-3885